Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana

Clinical Infectious Diseases

Volumn 41, Issue 4, 2005, Pages 461-469

  Tappero, Jordan W ^a,e   Bradford, Williamson Z ^b,c   Agerton, Tracy B ^a,c   Hopewell, Philip ^b,c   Reingold, Arthur L ^c   Lockman, Shahin ^a,e   Oyewo, Aderonke ^e   Talbot, Elizabeth A ^a,e   Kenyon, Thomas A ^a,e   Moeti, Themba L ^e   Moffat, Howard J ^e   Peloquin, Charles A ^d,f  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e Department of HIV AIDS Prevention and Care   (Botswana)

^f NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; BOTSWANA; CONTROLLED STUDY; COUGHING; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SPUTUM CULTURE; THORAX RADIOGRAPHY;

ADULT; ANTITUBERCULAR AGENTS; BOTSWANA; COMORBIDITY; ETHAMBUTOL; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 23244459431     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431984     Document Type: Article

References (39)

1. Treatment of tuberculosis. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. MMWR Recomm Rep 2003; 52(RR-11):1-77.
2. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274:945-51.
3. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179-84.
4. Bradford WZ, Martin JN, Reingold AL, Schecter GF, Hopewell PC, Small PM. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 1996; 348:928-31.
5. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993; 342:332-7.
6. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6-month) mortality. Am Rev Respir Dis 1992; 146:849-54.
7. Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV)-seropositive compared with HIV-seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144:750-5.
8. Perriens JH, St. Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332:779-84.
9. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications. N Engl J Med 1993; 329:1122-3.
10. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 1992; 327:1817-8.
11. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995; 332:336-7.
12. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998; 113:1178-83.
13. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127:289-93.
14. Gurumurthy P, Ramachandran G, Kumar AKH, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004; 48:4473-5.
15. Choudhri SH, Hawken M, Gathua S, et al. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis 1997; 25:104-11.
16. Taylor B, Smith PJ. Does AIDS impair the absorption of antituberculosis agents? Int J Tuberc Lung Dis 1998; 2:670-5.
17. Jaruratanasirikul S. The pharmacokinetics of oral rifampicin in AIDS patients. J Med Assoc Thai 1998; 81:25-8.
18. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167:1341-7.
19. Weiner M, Senator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. The Tuberculosis Trials Consortium. Clin Infect Dis 2005; 40:1481-91.
20. Kenyon AS, Flinn PE, Layloff TP. Rapid screening of pharmaceuticals by thin-layer chromatography: analysis of essential drugs by visual methods. J Aoac Int 1995; 78:41-9.
21. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy 1998; 18:1205-11.
22. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999;43:568-72.
23. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 3:703-10.
24. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 115:12-8.
25. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41:2670-9.
26. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169-83.
27. Peloquin CA. Pharmacological issues in the treatment of tuberculosis. Ann NY Acad Sci 2001; 953:157-64.
28. Peloquin CA. Antituberculosis drugs: pharmacokinetics. In: Heifets L, ed., Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:59-88.
29. Zhu M, Starke JR, Burman WJ, et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 2002; 22:686-95.
30. Zhu M, Burman WJ, Starke JR, et al. Population pharmacokinetic modeling of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis 2004; 8: 1360-1367.
31. Auclair B, Burman WJ, Stambaugh JJ, Berning SB, Ashkin D, Peloquin CA. Pharmacokinetics of isoniazid and rifampin in adults with tuberculosis. Am J Respir Crit Care Med 1999; 159:A16.
32. Perlman DC, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. Clin Infect Dis 2004; 38:556-64.
33. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2002; 51:214-5.
34. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353:1843-7.
35. Long MW, Snider Jr DE, Farer LS. US Public Health Service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119:879-94.
36. Peloquin CA. What is the right dose of rifampin? Int J Tuberc Lung Dis 2003; 7:3-5.
37. McDermott W, Ormond L, Muschenheim C, Deuschle K, McCune RM, Tompsett R. Pyrazinamide-isoniazid in tuberculosis. Am Rev Tuberc 1954; 69:319-33.
38. McLeod HM, Hay D, Stewart SM. The use of pyrazinamide plus isoniazid in the treatment of pulmonary tuberculosis. Tubercle 1959; 40:14-20.
39. Doster B, Murray FJ, Newman R, Woolpert SF. Ethambutol in the initial treatment of pulmonary tuberculosis: US Public Health Service tuberculosis therapy trials. Am Rev Respir Dis 1973; 107:177-90.